Table 1. Proposed drug combinations with NTG and standard of care in different cancers.

Disease	Targets	Drug combination
Breast cancer	Increase chemo/radio-sensitivity, improve EPR effect, target tumour-associated macrophages	Aspirin [49] Zoledronic acid [10]
Prostate	Increase chemo/radio-sensitivity, improve EPR effect, increase cytotoxicity, microtubule disruption	Statins (NCT01992042) Mebendazole [50] Metformin (NCT01561482)
NSCLC	Increase chemo/radio-sensitivity, improve EPR effect, AMPK/mTOR, COX-2 inhibition and immunomodulation	Metformin (NCT01997775) Diclofenac or Celecoxib (NCT00520845)
Melanoma	Microtubule disruption, anti-angiogenic and immunomodulation	Diclofenac or Celecoxib [51] Mebendazole [52] Cimetidine [53]
Colorectal	Microtubule disruption, AMPK/mTOR, immunomodulation, anti-histamine, COX-2	Cimetidine [36] Mebendazole [54] Metformin (NCT01941953) Aspirin [55]

Note that references to clinical trials or published papers are indicative of trials or case reports where the drug (or analogue) has been used for the specific indication.